Scopus BioPharma's Subsidiary — Duet Therapeutics — Announces Release of Preclinical Data Being Presented at 17th Annual Meeting of the Oligonucleotide Therapeutics Society

Data from two different studies benchmark Duet's proprietary bifunctional oligonucleotides against immune checkpoint inhibitors ("Checkpoint Inhibitors") in lymphoma and prostate tumor models in mice Studies indicate Duet's bifunctional oligonucleotid